UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
|
|
| (Check one): |
|
☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q
☐ Form 10-D ☐ Form N-CEN
☐ Form N-CSR |
|
|
|
|
For Period Ended: June 30, 2024 |
|
|
|
|
☐ Transition Report on Form 10-K |
|
|
|
|
☐ Transition Report on Form 20-F |
|
|
|
|
☐ Transition Report on Form 11-K |
|
|
|
|
☐ Transition Report on Form 10-Q |
|
|
|
|
☐ Transition Report on Form N-SAR |
|
|
|
|
For the Transition Period Ended: |
|
| |
|
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT
INFORMATION
Kazia Therapeutics Limited
Full Name of Registrant
(Translation of registrant’s name into English)
N/A
Former Name if
Applicable
Three International Towers Level 24 300 Barangaroo Avenue
Address of Principal Executive Office (Street and Number)
Sydney NSW 2000
City,
State and Zip Code
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following
should be completed. (Check box if appropriate)
|
|
|
|
|
| ☒ |
|
(a) |
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
| |
(b) |
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or
before the fifth calendar day following the prescribed due date; and |
| |
(c) |
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed
within the prescribed time period.
Kazia Therapeutics Limited (the “Registrant”) is unable to file with the Securities and Exchange
Commission, without unreasonable effort or expense, its Annual Report on Form 20-F for the fiscal year ended June 30, 2024 (the “Annual Report”) by October 31, 2024, the prescribed due date for such filing. Additional time is needed
for the Registrant to finalize its consolidated financial statements for the fiscal year ended June 30, 2024, and, as a consequence, for the Registrant’s independent registered public accounting firm to complete its audit procedures related
thereto. The Registrant anticipates that it will file the Annual Report no later than the fifteenth calendar day following the prescribed filing date.
PART IV — OTHER INFORMATION
|
|
|
|
|
|
|
|
|
|
|
|
|
| (1) |
|
|
|
Name and telephone number of person to contact in regard to this notification |
|
|
|
|
|
|
|
|
|
|
|
Dr. John Friend |
|
|
|
+61 |
|
|
|
2 9472 2677 |
|
|
|
|
(Name) |
|
|
|
(Area Code) |
|
|
|
(Telephone Number) |
|
|
|
| (2) |
|
|
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period
that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐ |
|
|
|
|
|
|
|
|
|
|
|
| (3) |
|
|
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or
portion thereof? Yes ☐ No ☒ |
|
|
|
|
|
|
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. |
Kazia Therapeutics Limited has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
| Date: |
|
November 1, 2024 |
|
|
|
By: |
|
|
|
/s/ John Friend |
|
|
|
|
|
|
Name: |
|
|
|
John Friend |
|
|
|
|
|
|
Title: |
|
|
|
Chief Executive Officer |